AMSTERDAM, The Netherlands, July 20, 2016 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it will highlight recent innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2016 Annual Meeting taking place at the Metro Toronto Convention Centre in Toronto, Ontario, Canada, from July 20-23, 2016.
Wright will feature its full range of lower extremities and biologics at exhibit booth #119, including the following recent new product launches:
- INFINITY® Total Ankle Replacement (TAR) System – The lower profile design and straightforward surgical approach of the INFINITY® TAR system can expand access to less complicated primary cases and is an important addition to the continuum of care for end-stage ankle arthritis patients. Combined with the PROPHECY® Pre-Operative Navigation Alignment Technology, which utilizes computed tomography scans to create patient-specific ankle alignment guides, surgeons have a visual plan that details implant placement in advance of the actual surgery, which can facilitate the alignment of the TAR components during surgery, reduce the amount of standard instrumentation required in the operating room and streamline the surgical procedure.
- AUGMENT® Bone Graft – Backed by comprehensive clinical data, including Level-1 evidence generated from the largest prospective, randomized, controlled clinical trial ever conducted in hindfoot and ankle fusion, AUGMENT® Bone Graft is the first clinically proven protein therapeutic to offer an alternative to autograft in ankle and/or hindfoot fusion procedures. The pivotal clinical trial data demonstrate that AUGMENT® Bone Graft offers clinical outcomes equivalent to autogenous bone graft, while simultaneously avoiding the additional surgery required to harvest autograft bone graft tissue that can result in site-specific complications and/or prolonged harvest site pain in some patients.
- SALVATION® Limb Salvage System – The SALVATION® Limb Salvage System is a comprehensive portfolio of products that is designed to address fractures, nonunion and complex foot and ankle deformities and is the first complete portfolio of products to be specifically indicated for use to treat neuropathic osteoarthropathy (commonly referred to as Charcot foot), a deformity that results from nerve damage in the foot or ankle.
Robert Palmisano, president and chief executive officer, commented, “We have continued to expand our broad product portfolio to further extend our leadership position in the fast growing lower extremities and biologics markets. Our AUGMENT Bone Graft provides a breakthrough therapeutic option as an alternative to autograft in ankle and hindfoot fusion procedures, and the INFINITY ankle’s lower profile design and simplified surgical approach is an important addition to the continuum of care for end-stage ankle arthritis patients. In addition, we have a unique opportunity to address advanced reconstructive, limb salvage, and Charcot cases with the launch of our SALVATION product portfolio. The initial response from physicians has been very strong, and we expect to build the market for SALVATION by focusing on training and education of foot and ankle physicians who specialize in treating limb salvage cases.”
Wright is also conducting medical education and training courses during the AOFAS annual meeting in its mobile training lab. These courses will address total ankle arthroplasty, Charcot reconstruction and limb salvage, and ankle and hindfoot fusion using Augment® Bone Graft. More information on Wright Medical’s products can be found at www.wright.com.
Internet Posting of Information
Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com. The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.
About Wright Medical Group N.V.
Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. For more information about Wright, visit www.wright.com.
WRIGHT®, INFINITY®, PROPHECY®, AUGMENT®, and SALVATION® are trademarks of Wright Medical Group N.V. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995.Forward-looking statements generally can be identified by the use of words such as “will,” “anticipate,” “expect,” “plan,” “can,” “could,” “may,” “believe,” and other words of similar meaning. Forward-looking statements in this press release include, but are not limited to, statements about the potential future growth of the upper extremities, lower extremities and biologics markets, the potential market size for our products, and the potential market acceptance and clinical benefits and performance of our products. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that competitive products achieve greater clinical success or market acceptance than our products, or that our products, for whatever reason, are less successful or clinically effective than presently anticipated, the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims and product recalls; pending and threatened litigation; competitor activities; and the other risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K, filed with the SEC on February 23, 2016. Investors should not place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Investors & Media: Julie D. Tracy Sr. Vice President, Chief Communications Officer Wright Medical Group N.V. (901) 290-5817 firstname.lastname@example.org
Source:Wright Medical Group N.V.